PORT WASHINGTON, N.Y., Aug. 4, 2011 (GLOBE NEWSWIRE) -- Aceto Corporation (Nasdaq:ACET), a global leader in the marketing and distribution of pharmaceutical intermediates and active ingredients, finished dosage form generics, nutraceutical products, agricultural protection products and specialty chemicals today announced that Rising Pharmaceuticals Inc, its generic finished dosage form subsidiary, has launched the 250 mg and 500 mg strengths of Disulfirm Tablets, the first approved generic version of Teva’s Antabuse Tablets®, following the U.S. Food and Drug Administration (FDA) approval of an Abbreviated New Drug Application (ANDA). According to IMS Health data, U.S. brand sales for Antabuse®, which is used to treat chronic alcoholism, were approximately $19 Million for the twelve months ended December 31, 2010.
